Discover. Oncology最新文献

{"title":"The effect of delays in cancer surgery due to the COVID-19 pandemic on cancer resectability and postoperative mortality in different tumor entities.","authors":"Antonia L Stengler, Jörg Kleeff, Lisa Rieder, James C Glasbey, Aneel A Bhangu, Ewen M Harrison, Ulrich Ronellenfitsch","doi":"10.1007/s12672-026-04430-5","DOIUrl":"https://doi.org/10.1007/s12672-026-04430-5","url":null,"abstract":"","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"17 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiogenomics deciphers tumor heterogeneity in hepatocellular carcinoma and combined hepatocellular-cholangiocarcinoma.","authors":"Yi Wang, Shichen Miao, Xiao Wang, Weiren Liu, Yinghong Shi","doi":"10.1007/s12672-026-05101-1","DOIUrl":"https://doi.org/10.1007/s12672-026-05101-1","url":null,"abstract":"<p><strong>Background: </strong>Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a highly heterogeneous cancer with limited knowledge of molecular features and prognosis. To compare the molecular features of cHCC-CCA with different subtypes of hepatocellular carcinoma (HCC) and to investigate the biological meanings of prognostic radiomic features in cHCC-CCA.</p><p><strong>Methods: </strong>We performed an integrative analysis to investigate the heterogeneity of cHCC-CCA and HCC by combining transcriptomic and radiomic approaches. RNA sequencing revealed distinct transcriptomic profiles between cHCC-CCA and HCC. For radiomic analysis, an eight-feature radiomic signature was constructed using preoperative contrast-enhanced MRI to predict overall survival in cHCC-CCA, and its prognostic significance was validated in an external dataset. Furthermore, weighted gene co-expression network analysis was employed to correlate radiomic features with underlying biological pathways.</p><p><strong>Results: </strong>LR-M subtype of cHCC-CCA exhibited more aggressive characteristics and immunosuppressive tumor microenvironment compared with LR-4/5 subtype, HCC with rim arterial-phase hyperenhancement (rim-APHE) and HCC without rim-APHE. The radiomic signature was correlated with overall survival (hazard ratio [HR], 5.47; 95% CI:2.08, 7.23, p = 0.006) in the cHCC-CCA validation cohort. Three types of prognostic radiomic features were correlated with distinct pathways: fatty acid metabolism, signaling pathways regulating pluripotency of stem cells and T cell receptor signaling pathway, respectively. Original_Glszm_GrayLevelNonUniformity might reflect the upregulation of fatty acid metabolism and immune suppression of cHCC-CCA.</p><p><strong>Conclusions: </strong>We illustrated the heterogeneity of subtypes of HCC and cHCC-CCA, which provides insights into the differentiation of primary liver cancer. Correlation of prognostic radiomic features with transcriptome profiles in cHCC-CCA enables noninvasive evaluation of tumor microenvironment.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematologic malignancies burden in China compared with the United States 1990-2021 and projections to 2040.","authors":"Wenshuai Zheng, Rui Qin, Hang Dong, Wentao Xiong, Xuan Zhou, Mingjuan Liu, Lixun Guan","doi":"10.1007/s12672-026-05146-2","DOIUrl":"https://doi.org/10.1007/s12672-026-05146-2","url":null,"abstract":"<p><strong>Background: </strong>Hematologic malignancies, including leukemia, non-Hodgkin lymphoma (NHL), multiple myeloma (MM), and Hodgkin lymphoma (HL), represent some of the most prevalent cancers. This study aims to comprehensively analyze the epidemiological trends of these malignancies in China.</p><p><strong>Methods: </strong>Using data from the Global Burden of Disease Study 2021 (GBD 2021), we conducted a detailed assessment of incidence cases, deaths, disability-adjusted life years (DALYs), and corresponding age-standardized rates (ASR) of hematologic malignancies in China. Additionally, we compared the disparity in disease burden between China and the United States (US).</p><p><strong>Results: </strong>In 2021, the incidence cases, deaths, and DALYs of all hematologic malignancies reached 238051.31, 117187.70, and 3894866.98, respectively, in China. From 1990 to 2021, although the age-standardized incidence rates (ASIR) of leukemia, MM, and NHL increased, the age-standardized death rates (ASDR) and age-standardized DALYs rates (ASDALYR) declined for all subtypes of hematologic malignancies, with the exception of MM. The ASIR of all subtypes of hematologic malignancies in the US was significantly higher than that in China, while the disparity of ASDALYR between the two countries was smaller. The ASRs for all subtypes of hematologic malignancies exhibited a positive correlation with age and were generally higher in males than in females. High body mass index (BMI) emerged as a significant risk factor contributing to deaths from all hematologic malignancies, and tobacco remains the leading contributor to leukemia-related deaths. Projections indicate that the burden of MM will continue to increase from 2022 to 2040.</p><p><strong>Conclusions: </strong>While the ASIR of hematologic malignancies has risen over recent decades, the ASDR and ASDALYR have showed a decreasing trend, reflecting China's efforts in reducing the burden of these diseases. However, the disparity in disease burden between China and the US underscores the substantial potential for improving the diagnosis, treatment, and care levels in China.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptional heterogeneity of tumor-associated high endothelial venules defines inflammatory and stress-metabolic states with distinct prognostic associations.","authors":"Hwal-Seok Choi, Yongjun Lee, Jin-Woo Choi, So-Jeong Kim, Hyunji Kim, Hyo-Kyung Pak, Jin Roh, Chan-Sik Park","doi":"10.1007/s12672-026-05162-2","DOIUrl":"https://doi.org/10.1007/s12672-026-05162-2","url":null,"abstract":"<p><p>Tumor-associated high endothelial venules (TA-HEVs) mediate lymphocyte trafficking into tumors and modulate the tumor microenvironment, with reported effects on clinical outcomes. However, reports have described discordant associations across cancers and microenvironmental contexts. Studies on state-specific, pan-cancer analyses of TA-HEV function remain limited. We integrated publicly available single-cell RNA sequencing datasets from 11 cancer types. Functional features of TA-HEVs were inferred by pathway enrichment and single-cell gene-set scoring for pathway gene sets. State-specific programs were applied to The Cancer Genome Atlas dataset to assess their clinical impact. We constructed a comprehensive atlas of tumor-associated endothelial cells and identified TA-HEV subclusters. Five TA-HEV subclusters were grouped into two functional states: inflammatory and stress-metabolic. The inflammatory TA-HEVs were enriched for innate immune stimulation, cytokine/chemokine signaling, and MHC class II antigen presentation, whereas the stress-metabolic TA-HEVs were characterized by the unfolded protein response, heat shock pathways, oxidative phosphorylation, and ATP biosynthesis. Across cancers, the stress-metabolic TA-HEV state was generally associated with worse prognosis, while the inflammatory TA-HEV state showed context-dependent associations. Together, these findings define TA-HEVs as a heterogeneous endothelial population comprising distinct functional states with divergent clinical associations, providing a pan-cancer framework for interpreting TA-HEV signals in tumor biology.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative analysis of tumor-educated platelets for stage-specific diagnosis, prognosis, and therapy in ovarian cancer.","authors":"Shaimaa Gamal Gahin, Mostafa S Ibrahim, Eman Badr","doi":"10.1007/s12672-026-05011-2","DOIUrl":"https://doi.org/10.1007/s12672-026-05011-2","url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer (OC) remains one of the most lethal gynecological cancers worldwide. Despite advances in diagnosis, OC is mostly detected at late stages due to undefined symptoms. Therefore, identifying feasible, reliable, non-invasive biomarkers for early detection and disease stratification of OC is crucial. Tumor-educated platelets (TEPs) have emerged as a promising source for liquid biopsy, harboring oncogenic mRNA signatures that reflect the tumor microenvironment. In this study, we investigated TEP-mRNAs to identify stage-specific biomarkers for OC diagnosis and prognosis, while uncovering disease progression mechanisms and potential therapeutic targets.</p><p><strong>Methods: </strong>An integrative framework that combines machine learning (ML) techniques with differential expression analysis was used to identify candidate biomarker genes (CBGs) across OC stages. Random forests were used to assess the diagnostic accuracy of CBGs, and survival analysis was used to evaluate their prognostic significance. In silico drug screening was performed to prioritize potential anticancer drugs identified via a drug-gene network. Finally, pathway enrichment analysis was performed to elucidate the progression mechanisms specific to each stage. Multiple datasets have been utilized for analysis and validation.</p><p><strong>Results: </strong>The proposed integrative analysis revealed 50 CBGs across the four OC stages. Predictive models have been trained utilizing the CBGs expression profiles and achieved F1-scores of 95%, 95%, 80%, and 93% for stages 1, 2, 3, and 4, respectively. Focusing on CBGs with prognostic relevance, survival analysis identified seven candidate genes associated with patient outcomes: PIK3AP1 and IARS2 (stage 1); CTSW, QSOX1, and CASP1 (stage 2); GZMB (stage 3); and CA1 (stage 4). In silico drug screening and drug-gene network analysis prioritized 21 FDA-approved drugs for further evaluation. Pathway enrichment analysis revealed 22 stage-specific pathways (SSPs), highlighting key molecular changes in OC, including kinesins and collagen chain trimerization for early stages.</p><p><strong>Conclusion: </strong>The proposed framework integrates ML and bioinformatics techniques for stage-specific biomarker discovery in OC using TEP mRNAs. The candidate biomarkers exhibit prognostic and diagnostic potential. Beyond early detection, the framework supports the potential clinical utility of TEP mRNAs for risk stratification and patient classification. Furthermore, the identified drug candidates provide a basis for further investigation toward more targeted treatment approaches. Overall, this study highlights the promising role of TEP mRNAs as a non-invasive tool for early diagnosis and prognosis.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"17 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes of trifluridine/tipiracil with or without bevacizumab in refractory metastatic colorectal cancer: a multicenter cohort study from Turkey.","authors":"Selami Bayram, Bahadir Koylu, Maral Martin Mildanoglu, Bilgin Demir, Hayati Arvas, Ozan Deniz Guven, Mustafa Serkan Alemdar, Tahir Yerlikaya, Fatih Selcukbiricik, Ahmet Bilici, Mukremin Uysal, Aysegul Kargi, Ali Murat Tatli, Muharrem Okan Cakir, Mustafa Ozdogan","doi":"10.1007/s12672-026-05158-y","DOIUrl":"https://doi.org/10.1007/s12672-026-05158-y","url":null,"abstract":"<p><strong>Background: </strong>Trifluridine/tipiracil (FTD/TPI; TAS-102) is an established later-line treatment option for refractory metastatic colorectal cancer (mCRC), and randomized evidence supports the addition of bevacizumab. However, real-world data from Turkey are limited.</p><p><strong>Methods: </strong>We conducted a multicenter retrospective cohort study of adults with metastatic colorectal cancer (mCRC) who received FTD/TPI plus bevacizumab (combination) or FTD/TPI monotherapy in routine clinical practice between June 2021 and May 2025, with follow-up updated until September 25, 2025. Overall survival (OS) was the primary endpoint, and progression-free survival (PFS), response outcomes in radiologically evaluable patients, and safety were secondary endpoints. Survival was analyzed using Kaplan-Meier estimates and log-rank tests, with hazard ratios estimated using Cox regression. A prespecified multivariable Cox model for OS was adjusted for ECOG performance status, number of metastatic sites, liver metastasis, age group, and treatment group.</p><p><strong>Results: </strong>Seventy-eight patients were included (combination therapy, n = 57; monotherapy, n = 21). Median OS was 8 months (95% CI, 6.17-9.83) in the combination group and 6 months (95% CI, 5.03-6.97) in the monotherapy group (log-rank p = 0.437). Median PFS was 4 months (95% CI, 2.83-5.16) versus 3 months (95% CI, 1.92-4.07) (log-rank p = 0.409). Best radiologic response was evaluable in 65 patients. In univariable Cox regression, treatment group was not significantly associated with OS or PFS. In the multivariable Cox model for OS, treatment group remained not significantly associated with OS (adjusted HR 1.251, 95% CI 0.644-2.427; p = 0.509), whereas ECOG 1 (vs. 0) and liver metastasis (yes vs. no) were associated with worse OS. Hematologic toxicity was the dominant safety signal in both groups, and no unexpected safety signals were observed.</p><p><strong>Conclusions: </strong>In this multicenter Turkish real-world cohort, FTD/TPI-based therapy was feasible with manageable toxicity in heavily pretreated refractory mCRC. Comparative survival estimates between combination therapy and monotherapy were not statistically significant in unadjusted or adjusted analyses and should be interpreted as exploratory in light of baseline imbalances, subgroup-size asymmetry, and residual confounding. These findings complement, rather than challenge, the comparative efficacy estimates established in randomized trials such as SUNLIGHT.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated bulk and single-cell transcriptomic analyses identify transcriptome-defined groups and EGFR-associated microenvironmental programs in glioma.","authors":"Yuanhan Wang, Long Li, Xing Hu, Longhu Han, Yihan Zhang, Zhisen Zhou, Wei Liu, Song Yang","doi":"10.1007/s12672-026-05138-2","DOIUrl":"https://doi.org/10.1007/s12672-026-05138-2","url":null,"abstract":"<p><strong>Background: </strong>Glioma exhibits significant molecular heterogeneity, necessitating improved understanding of molecular subtypes for personalized treatment strategies.</p><p><strong>Methods: </strong>This study integrated bulk RNA sequencing (GSE35169) to derive transcriptome-defined groups and single-cell RNA sequencing (GSE131928) to characterize cellular heterogeneity and EGFR-associated malignant cell programs. Differential gene expression analysis identified subtype-specific biomarkers. Single-cell analysis included cell-type annotation, pseudotime trajectory, and cell-cell communication inference, with malignant cells stratified by EGFR expression to interrogate EGFR-associated programs. Key findings were validated by qRT-PCR in glioma cell lines (LN229, U251) and normal astrocytes (NHA).</p><p><strong>Results: </strong>Two transcriptome-defined groups were identified from bulk RNA-seq. In scRNA-seq, the EGFR-high malignant cell state showed enrichment of ECM-related genes (IGFBP2, COL1A1) and enhanced PI3K-AKT, focal adhesion, and angiogenic signaling, with predominant stromal-to-tumor communication (EGF/AREG→EGFR, TGFB1→TGFBR2). The EGFR-low malignant cell state exhibited higher expression of immune-related genes (CXCL10, IL6, STAT1). Functional enrichment analysis based on differentially expressed genes (FDR < 0.05) indicated significant enrichment of interferon signaling and JAK-STAT pathway-related gene sets in the EGFR-low group. Pseudotime analysis revealed gradual transcriptional transitions between proliferation, hypoxia, and immune programs. qRT-PCR validation confirmed elevated EGFR, IGFBP2, and COL1A1 in U251 cells, and higher CXCL10, IL6, and STAT1 in LN229 cells.</p><p><strong>Conclusion: </strong>This study identifies bulk transcriptome-defined groups and reveals EGFR-associated malignant cell programs linked to distinct microenvironmental interaction patterns. The EGFR-high malignant cell state features proliferative and angiogenic programs, while the EGFR-low malignant cell state shows enhanced immune infiltration. These findings provide molecular evidence for precision classification and subtype-specific therapeutic strategies.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leveraging mitochondrial dynamics-related risk signatures to predict the prognosis and tumor microenvironment of lung adenocarcinoma.","authors":"Li Xu, Danting Zheng, Jisong Zhang, Huihui Hu, Liangliang Dong, Enguo Chen","doi":"10.1007/s12672-026-05038-5","DOIUrl":"https://doi.org/10.1007/s12672-026-05038-5","url":null,"abstract":"<p><strong>Background: </strong>Lung adenocarcinoma (LUAD) is a highly heterogeneous disease, bringing daunting challenges in prognosis prediction. Alterations in mitochondrial dynamics (MD) are crucial in tumor generation and progression. Therefore, this study is the first to build a prognostic model based on mitochondrial dynamics-related genes (MDRGs) to predict microenvironment and potential drugs for LUAD.</p><p><strong>Methods: </strong>LUAD transcriptomic data were sourced from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO), respectively. First, differentially expressed genes (DEGs) were screened between normal and LUAD samples in the TCGA cohort. The intersection of DEGs and MDRGs yielded differentially expressed MDRGs (DE-MDRGs). Then, a prognostic model was constructed through univariate Cox regression, LASSO Cox regression, and multivariate Cox regression analysis. A nomogram was graphed using clinical factors and the MD-related risk score (MDRS). The predictive performance of the model and the nomogram was evaluated using ROC curves. Finally, analyses on tumor microenvironment (TME), mutation, and predicted in vitro drug response were undertaken.</p><p><strong>Results: </strong>A prognostic model based on 8 MDRGs (SLC52A3, HMGA2, CPS1, GLS2, CYP27A1, CFTR, STAR, and DRP2) was established, demonstrating relatively accurate predictive ability. The low-MDRS group had higher levels of immune cell infiltration, such as aDCs, B cells, neutrophils, and tumor-infiltrating lymphocytes. We also discovered that the tumor mutation burden in the high-MDRS group was considerably higher than that in the low-MDRS group. Additionally, the low-MDRS group was more sensitive to AZD8055, ZM447439, ERK-6604, SB505124, Tozasertib, and BMS-754807, while the high-MDRS group was more sensitive to BI-2536 and Venetoclax.</p><p><strong>Conclusion: </strong>This work set up a prognostic model for LUAD based on 8 MDRGs, pinpointing promising biomarkers and targets for LUAD treatment.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge mapping of ⁹⁰Y transarterial radioembolization combined with immunotherapy in hepatocellular carcinoma: a bibliometric analysis.","authors":"Song-Nian He, Chu-Hui Zeng, Rui-Jie Du, Yi-Xuan Yang, Hai-Dong Zhu","doi":"10.1007/s12672-026-05154-2","DOIUrl":"https://doi.org/10.1007/s12672-026-05154-2","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with substantial mortality globally. The synergistic potential between immunotherapy and yttrium-90 transarterial radioembolization (⁹⁰Y-TARE) has stimulated extensive research into HCC combined therapeutic strategies. However, a comprehensive bibliometric analysis elucidating the evolutionary trajectory, research trends, and collaborative networks within this field remains absent. Unlike conventional systematic reviews, which are inherently subjective and lack the capacity for large-scale quantitative synthesis, bibliometric analysis offers a robust, data-driven approach to construct a holistic knowledge atlas. A total of 143 relevant publications were extracted from the Web of Science Core Collection (WoSCC) database, spanning 1 January 2003 to 24 October 2025. Utilizing VOSviewer, CiteSpace, and the R package bibliometrix, a multidimensional analysis encompassing publication volume, journal impact, national/contributions, institutional collaborations, authorship networks, co-citation patterns, and keyword clustering was conducted. From 2015 to 2025, the number of publications in this field has steadily increased. The United States was the dominant contributor. Global institutional collaboration was limited, highlighting the need for multinational cooperation. Co-citation and keyword analyses revealed three research frontiers: mechanisms of radio-immunologic synergy, optimization of treatment sequencing and dosimetry, and predictive biomarker development. Future research requires more phase III trials, incorporating multi-omics technologies and individualized dosimetry models to validate survival benefits and explore more precise immuno-combination strategies.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric parotid mucoepidermoid carcinoma: a case report.","authors":"Gashaw Arega, Abdurrhman Kedir Hamza, Leul Adane, Mesay Tilahun, Fitsum A Gemechu, Adino Melkamu Gobez","doi":"10.1007/s12672-026-05054-5","DOIUrl":"https://doi.org/10.1007/s12672-026-05054-5","url":null,"abstract":"<p><p>Salivary gland neoplasms are rare, comprising less than 5% of pediatric head and neck tumors, with mucoepidermoid carcinoma (MEC) being the most common malignant type. MEC in the parotid gland is exceedingly rare in children. Histologically, MEC tumors consist of squamous cells, mucus-secreting cells, and lymphoid infiltration, reflecting their complex cellular composition. This case report presents a 9-year-old female with a one-year history of progressive, painless swelling in the left cheek, accompanied by facial nerve palsy. Imaging studies revealed a heterogeneously enhancing mass in the left parotid gland with features suggestive of malignancy. Surgical resection was performed, and histopathologic examination confirmed MEC with perineural invasion. The patient subsequently received adjuvant radiotherapy and chemotherapy. Post-surgery, she demonstrated good healing, and with no significant complications from the adjuvant therapy. Literature review described in this case report provides insights into the prevalence, diagnostic approaches, histopathological characteristics, treatment modalities, and prognostic factors for MEC, offering a comprehensive understanding of this uncommon pediatric malignancy.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}